| Methods |
Double‐blind, placebo‐controlled, parallel group
Randomisation by prepared and numbered identical study packs |
| Participants |
UK, single centre
40 patients. T: 18, C: 22
Age: T: 73 years, C: 75 years
Male: 63%
Inclusion: acute ischaemic stroke within the previous 24 hours with a mean casual SBP level ≥ 140 mm Hg or
DBP level ≥ 90 mm Hg
Randomisation done before neuroimaging and those with non‐ischaemic stroke were withdrawn from the study |
| Interventions |
T: 5 mg lisinopril po once daily
C: matching placebo
Rx: 14 days
Dose was increased to 10 mg or 2 placebos on day 7 if SBP ≥ 140 mmHg or DBP ≥ 90 mmHg |
| Outcomes |
Casual brachial artery BP monitoring at 5‐minute intervals during a 30‐minute period with a validated monitor (A&D UA 767)
NIHSS score at day 14, Barthel score and modified Rankin scale at day 14 and day 90 |
| Notes |
Ex: severe carotid stenosis, significant aortic stenosis, cardiac failure, MI within past 6 months, dysphagia, dehydration, adverse reactions to ACEI, and pre‐stroke modified Rankin score > 2 |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Probably done |
| Allocation concealment? |
Low risk |
Probably done |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
High risk |
During 90‐day follow up 1 patient from lisinopril died, 2 placebo‐treated patients underwent rating before day 90 (1 moved to another hospital and 1 declined further study participation after the treatment period) |
